Vaxcyte Inc., a clinical-stage vaccine innovation company, has announced the advancement of its modified VAX-31 infant Phase 2 randomized, dose-finding study to the third and final stage. This study is focused on evaluating the safety, tolerability, and immunogenicity of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in comparison to Prevnar 20 (PCV20) in healthy infants. The study protocol has been modified to include a new dose arm, the VAX-31 Optimized Dose, with the majority of serotypes dosed at 4.4mcg and the balance at 3.3mcg, while discontinuing enrollment in the Low Dose arm. The study aims to enroll approximately 900 participants, with the Middle and High Dose arms continuing as planned. Vaxcyte intends to release topline data from the primary immunization series and the booster dose either sequentially or together by the end of the first half of 2027. Results from the study have not yet been presented.